Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - Priority Announcement: Hepatology

Direct Payment

$50,000.00

Does microbial translocation contribute to the accelerated liver fibrosis progression seen in HCV/HIV co-infected patients?

EF 2008-09

Résumé
This project focuses liver disease in patients who are chronically infected with two viruses--the hepatitis C virus (HCV) and the human immunodeficiency virus (HIV). It has the potential to improve the health of Canadians by providing information about a new method for assessing liver injury, FibroScan, and by enhancing understanding of liver injury in patients with HIV/HCV co-infection. About one-third of people infected with HIV are co-infected with HCV and liver disease is a significant cause of death among them. The goal of this project is to determine whether one specific activity of HIV--its killing of immune cells in the gut--contributes to liver disease in HIV/HCV co-infected patients. This process is thought to increase the number of bacteria that are able to enter into the blood from the digestive track and is called bacterial translocation. We will look for positive correlations between markers of bacterial translocation and liver injury. We will first measure liver injury by inspection of liver biopsy tissue. The second method, elastography, is very new. It uses a FibroScan machine, which measures liver stiffness. Liver stiffness is positively correlated with the amount of scar tissue in patients with hepatitis C. Unlike liver biopsy, elastography is non-invasive and allow serial measurements over time. In the first part of this project, we will see if there is a positive relationship between serum markers of bacterial translocation and liver histology and stifness. In the second part, we will follow patients over time to see if those who have high levels of bacterial markers at first experience more rapid increases in liver stiffness over time than patients with low levels. This project will increase knowledge of fibrosis progression in co-infected patients. It will provide information about the utility of a non-invasive, new technology in this population, the FibroScan. Non-invasive techniques facilitate access to care, early diagnosis and treatment.
Programme
Fellowship - Priority Announcement: Hepatology
Bénéficiaire
Emplacement
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
178340
Name
Vachon Marie-Louise C
Region
New York
Country
United States of America
Orgtype
Research Institution
Partnername
The Canadian Association for the Study of Liver
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Does microbial translocation contribute to the accelerated liver fibrosis progression seen in HCV/HIV co-infected patients?
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Hepatology
Keyworddelim
Co-Infection; Elisa; Fibroscan; Hepatitis C; Hiv; Liver Fibrosis; Liver Fibrosis Serum Markers; Microbial Translocation; Non-Invasive Technique; Rt-Pcr
Abstract
This project focuses liver disease in patients who are chronically infected with two viruses--the hepatitis C virus (HCV) and the human immunodeficiency virus (HIV). It has the potential to improve the health of Canadians by providing information about a new method for assessing liver injury, FibroScan, and by enhancing understanding of liver injury in patients with HIV/HCV co-infection. About one-third of people infected with HIV are co-infected with HCV and liver disease is a significant cause of death among them. The goal of this project is to determine whether one specific activity of HIV--its killing of immune cells in the gut--contributes to liver disease in HIV/HCV co-infected patients. This process is thought to increase the number of bacteria that are able to enter into the blood from the digestive track and is called bacterial translocation. We will look for positive correlations between markers of bacterial translocation and liver injury. We will first measure liver injury by inspection of liver biopsy tissue. The second method, elastography, is very new. It uses a FibroScan machine, which measures liver stiffness. Liver stiffness is positively correlated with the amount of scar tissue in patients with hepatitis C. Unlike liver biopsy, elastography is non-invasive and allow serial measurements over time. In the first part of this project, we will see if there is a positive relationship between serum markers of bacterial translocation and liver histology and stifness. In the second part, we will follow patients over time to see if those who have high levels of bacterial markers at first experience more rapid increases in liver stiffness over time than patients with low levels. This project will increase knowledge of fibrosis progression in co-infected patients. It will provide information about the utility of a non-invasive, new technology in this population, the FibroScan. Non-invasive techniques facilitate access to care, early diagnosis and treatment.
Competitiondate
200810
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Vachon, Marie-Louise C
Approvedterm
2 ans 0 mois
Cihrcontribution2
PDD #351~ $50,000~ $0~